(Q83120849)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20200513%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Therapeutic protein-drug interactions and implications for drug development (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20200513%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

S-M Huang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20200513%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

H Zhao

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20200513%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J-I Lee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20200513%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

K Reynolds

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20200513%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

L Zhang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20200513%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

R Temple

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20200513%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

L J Lesko

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20200513%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

3 March 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20200513%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20200513%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20200513%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20200513%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

497-503

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20200513%20AND%20SRC:MED&resulttype=core&format=json

Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Drug interaction studies: study design, data analysis, and implications for dosing and labeling

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Predicting drug-drug interactions: an FDA perspective

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Drug interaction studies of therapeutic proteins or monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Drug interactions evaluation: an integrated part of risk assessment of therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Regulation of drug transporters during infection and inflammation.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Membrane transporters in drug development

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Transporters in drug development: advancing on the Critical Path

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

The International Transporter Consortium: a collaborative group of scientists from academia, industry, and the FDA

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.308

7 January 2021

Identifiers

DOI

10.1038/CLPT.2009.308

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20200513%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference